Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
{{output}}
Background: Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving standard therapy. ... ...
